The U.S. Food and Drug Administration (FDA) has awarded Evofem Biosciences a Qualified Infectious Disease Product (QIDP) Designation to EVO100 (Phexxi) for the prevention of chlamydia. Chlamydia has been reported to be responsible for up to half of all pelvic inflammatory disease (PID) cases and is the most frequently reported bacterial infection in the US. PID can lead to serious and long-term health problems in women, including infertility and ectopic pregnancy. The FDA’s QIDP designation qualifies Evofem Biosciences for an additional five years of market exclusivity for EVO100 (Phexxi). Evofem Biosciences develops products to address unmet medical challenges of women’s reproductive and sexual health.
Read more here.
More on: FDA News Regulatory